9:50 PM
 | 
Sep 24, 2008
 |  BC Extra  |  Clinical News

Medivir reports Phase IIa HCV data

Medivir (SSE:MVIR B) said TMC435350 had dose-dependant antiviral activity at four weeks both alone and in combination with standard care in the first cohort of 50 patients in the European...

Read the full 137 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >